Journal
MOLECULAR & CELLULAR ONCOLOGY
Volume 6, Issue 5, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/23723556.2019.1627273
Keywords
N-acetyl-aspartyl-glutamate (NAAG); glutamate carboxypeptidase II (GCPII); glutaminase inhibitor; glutamate reservoir; stable isotope-resolved metabolomics (SIRM)
Categories
Funding
- NIH [R01-CA193895, R01-CA 112314, 1S10OD025226-01, UL1 TR 001079]
- Allegheny Health Network-Johns Hopkins Cancer Research Fund
- Doris M. Weinstein Pancreatic Cancer Research Fund
Ask authors/readers for more resources
We uncovered the neurotransmitter N-acetyl-aspartyl-glutamate (NAAG) as a reservoir providing glutamate to promote cancer growth, and demonstrated that inhibition of NAAG hydrolysis by targeting glutamate carboxypeptidase II is a viable strategy for cancer therapy. Our study also suggests that NAAG concentration in plasma could be a non-invasive measurement to monitor cancer progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available